Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2021; 13(10): 1336-1366
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1336
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
Francesca Saffioti, Vasileios K Mavroeidis
Francesca Saffioti, Department of Gastroenterology and Hepatology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, Oxfordshire, United Kingdom
Francesca Saffioti, UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free Hospital, University College London, London NW3 2QG, United Kingdom
Vasileios K Mavroeidis, Department of Surgery, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, United Kingdom
Vasileios K Mavroeidis, Department of Transplant Surgery, North Bristol NHS Trust, Southmead Hospital, Bristol BS10 5NB, United Kingdom
Author contributions: Mavroeidis VK conceptualised the study; Both authors designed the study, did the literature search, analysis and interpretation of data, drafted the manuscript, made critical revisions and approved the final version.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasileios K Mavroeidis, MD, MSc, FRCS, FICS, MFSTEd, Surgeon, Department of Surgery, The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom. vasileios.mavroeidis@nhs.net
Received: March 29, 2021
Peer-review started: March 29, 2021
First decision: June 23, 2021
Revised: July 5, 2021
Accepted: August 23, 2021
Article in press: August 23, 2021
Published online: October 15, 2021
Core Tip

Core Tip: Cholangiocarcinoma (CCA) in primary sclerosing cholangitis (PSC) has become the leading cause of death. Major hepatic resection is commonly not possible in PSC patients to treat CCA, but overwhelming progress with excellent results in the last two decades has established an increasing role of protocolised combination of neoadjuvant chemoradiation and orthotopic liver transplantation. We review in detail, the incidence, as well as aspects of treatment and outcomes according to the different anatomical locations of CCA in PSC, through the viewpoint of historical evolution of treatment paradigms.